• 0.1% foam, cream, and gel, and 0.045% lotion: Mild to moderate acne vulgaris.
• 0.05% and 0.1% cream and gel: Stable plaque psoriasis.

Contraindicated in:

• OB: Pregnancy
• Lactation: Lactation.

Use Cautiously in:

• History of local irritation/sensitivity
• Personal/family history of skin cancer
• History of eczema
• Weather extremes
• Concurrent use of photosensitizers
• Women of reproductive potential
• Pedi: Safety and effectiveness not established in children <12 yr (cream, foam, and gel) and <9 yr (lotion).

Local: burning/stinging, dry skin, itching, peeling, photosensitivity, red skin, skin pain (psoriasis), worsening of psoriasis.

Drug-Drug:

• Concurrent use of other irritant/drying topical medications may risk of irritant/drying reactions.
• Concurrent use of oxidizing agents including benzoyl peroxide, may decrease effectiveness by inactivating tazarotene.
• ↑risk of photosensitivity reactions with other photosensitizing drugs, including fluoroquinolones, phenothiazines, sulfonamides, tetracyclines, and thiazides.

(Generic available)

• Cream (Tazorac): 0.05%; 0.1%;
• Foam (Fabior): 0.1%;
• Gel (Tazorac): 0.05%; 0.1%;
• Lotion (Arazlo): 0.045%;
• In combination with: halobetasol (Duobrii). See Appendix [not included in this PDA edition].

• Topical (Adults and Children 12 yr): Apply once daily (not recommended for use longer than 12 wk for acne or 12 mo for plaque psoriasis).
• Topical (Adults and Children 9 yr): Lotion: Apply once daily.

Arazlo, Fabior, Tazorac

• Has antihyperproliferative and anti-inflammatory effects; also normalizes differentiation.

• Decreased severity of acne vulgaris or plaque psoriasis.

Therapeutic Classification: antiacne agents, antipsoriatics, cosmetic agents

Pharmacologic Classification: retinoids

Absorption: A prodrug that is rapidly converted to its active form, tazarotenic acid. Minimal systemic absorption.

Distribution: Unknown.

Protein Binding: >99%.

Metabolism/Excretion: Highly metabolized and excreted via urine and feces.

Half-life: 8.1 hr.

(improvement in lesions)

• Instruct patient on correct technique for application.
• Caution patient to wear sunscreen and protective clothing to prevent photosensitivity reactions. Avoid tanning beds and sunlamps. Wind and cold weather may also irritate skin.
• Inform patient foam is flammable. Avoid fire, flame, or smoking during and immediately following application.
• Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
• May cause fetal harm. Advise females of reproductive potential to use an effective form of contraception during therapy and notify health care professional if pregnancy is planned or suspected or if breastfeeding.

taz-AR-oh-teen